Bone Biologics Corp Income Statement
BBLG|4 years of annual SEC 10-K data (FY2017-FY2020)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Bone Biologics Corp reported $1.1B in revenue and $3M in net loss for FY2020. Revenue has grown at a 0.0% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B |
| SG&A Expense | $1.4M | $2.7M | $4.0M | $6.4M |
| R&D Expense | $1.1M | $104.5K | $1.4M | $7.0M |
| Operating Income | -$2.4M | -$2.8M | -$2.6M | -$13.4M |
| Income Tax | $1.6K | $1.7K | $1.6K | $1.6K |
| Net Income | -$3.4M | -$4.4M | -$7.1M | -$17.0M |
| EPS (Basic) | - | - | - | $0.03 |
| EPS (Diluted) | -$0.47 | -$0.88 | -$1.81 | $0.02 |
| Shares Outstanding | 30.7M | 26.4M | 4.3M | 38.8M |
| Operating Margin | -0.2% | -0.3% | -0.3% | -1.3% |
| Profit Margin | -0.3% | -0.4% | -0.7% | -1.6% |